{"date":"2026-09-08","count":9,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6875-2026-09-08-2326-1x9suzt","company_id":"6875","company":"國邑*","market":"上櫃","industry":"生技醫療","date":"2026-09-08","time":"23:26:48","subject":"本公司吸入新藥L606用於治療間質性肺病相關肺高壓(PH-ILD)之全球第三期樞紐臨床試驗(Re-Spire)設計於2026年歐洲呼吸學會年會(ERS 2026)發表，展示實驗設計及目前進展","clause":"第53款","fact_date":"2026-09-08","cite_as":"公開資訊觀測站重大訊息：國邑*（6875），2026-09-08 23:26，「本公司吸入新藥L606用於治療間質性肺病相關肺高壓(PH-ILD)之全球第三期樞紐臨床試驗(Re-Spire)設計於20」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4735-2026-09-08-2107-1cemc3i","company_id":"4735","company":"豪展","market":"上櫃","industry":"生技醫療","date":"2026-09-08","time":"21:07:16","subject":"公告本公司一年內累積取得同一有價證券達本公司實收資本額20%以上","clause":"第20款","fact_date":"2026-09-08","cite_as":"公開資訊觀測站重大訊息：豪展（4735），2026-09-08 21:07，「公告本公司一年內累積取得同一有價證券達本公司實收資本額20%以上」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2026-09-08-1842-19yaivw","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2026-09-08","time":"18:42:33","subject":"代重要子公司Alvogen Korea Co., Ltd.公告召開2026年股東臨時會","clause":"第17款","fact_date":"2026-09-08","cite_as":"公開資訊觀測站重大訊息：美時（1795），2026-09-08 18:42，「代重要子公司Alvogen Korea Co., Ltd.公告召開2026年股東臨時會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6857-2026-09-08-1716-1kgkm7z","company_id":"6857","company":"宏碁智醫","market":"興櫃","industry":"生技醫療","date":"2026-09-08","time":"17:16:29","subject":"公告本公司薪資報酬委員會召集人及成員異動","clause":"第6款","fact_date":"2026-09-08","cite_as":"公開資訊觀測站重大訊息：宏碁智醫（6857），2026-09-08 17:16，「公告本公司薪資報酬委員會召集人及成員異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6857-2026-09-08-1716-1wci87i","company_id":"6857","company":"宏碁智醫","market":"興櫃","industry":"生技醫療","date":"2026-09-08","time":"17:16:11","subject":"本公司董事會決議召開民國115年第一次股東臨時會","clause":"第32款","fact_date":"2026-09-08","cite_as":"公開資訊觀測站重大訊息：宏碁智醫（6857），2026-09-08 17:16，「本公司董事會決議召開民國115年第一次股東臨時會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4105-2026-09-08-1707-5sbnzb","company_id":"4105","company":"東洋","market":"上櫃","industry":"生技醫療","date":"2026-09-08","time":"17:07:19","subject":"公告本公司115年8月份自結合併損益","clause":"第53款","fact_date":"2026-09-08","cite_as":"公開資訊觀測站重大訊息：東洋（4105），2026-09-08 17:07，「公告本公司115年8月份自結合併損益」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6657-2026-09-08-1541-13s4tig","company_id":"6657","company":"華安","market":"上市","industry":"生技醫療","date":"2026-09-08","time":"15:41:25","subject":"本公司股東參與源華智醫股份有限公司現金增資股款催繳公告","clause":"第51款","fact_date":"2026-09-08","cite_as":"公開資訊觀測站重大訊息：華安（6657），2026-09-08 15:41，「本公司股東參與源華智醫股份有限公司現金增資股款催繳公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2026-09-08-1504-ahwybv","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-09-08","time":"15:04:44","subject":"公告本公司董事會決議更換主辦輔導推薦證券商暨協辦輔導推薦證券商事宜","clause":"第44款","fact_date":"2026-09-08","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-09-08 15:04，「公告本公司董事會決議更換主辦輔導推薦證券商暨協辦輔導推薦證券商事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6539-2026-09-08-1421-1qldxi4","company_id":"6539","company":"麗彤","market":"興櫃","industry":"生技醫療","date":"2026-09-08","time":"14:21:35","subject":"公告本公司向關係人取得使用權資產(更正依取處第十六條規定評估之價格)","clause":"第17款","fact_date":"2026-08-11","cite_as":"公開資訊觀測站重大訊息：麗彤（6539），2026-09-08 14:21，「公告本公司向關係人取得使用權資產(更正依取處第十六條規定評估之價格)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}